Can multiple myeloma become a curable disease?

Haematologica

Volumn 96, Issue 9, 2011, Pages 1246-1248

  San Miguel, Jesús F ^a   Mateos, María Victoria ^a  

^a Centro de Investigacion del Cancer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; CORTICOSTEROID DERIVATIVE; LENALIDOMIDE; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CONTROL; CANCER STEM CELL; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; EDITORIAL; HIGH RISK PATIENT; HUMAN; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 80052345517     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.051169     Document Type: Editorial

References (24)

1. Kyle RA, Rajkumar SV. Mutiple Myeloma. N Engl J Med. 2004;351(18):1860-73
2. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood. 2010;115(18):3655-63
3. San-Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clinic Oncology. 2008;26(16):2761-6
4. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood. 2009;114(27):5436-43
5. Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599-605
6. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic transplantation for multiple myeloma. J Clin Oncol. 2010;28(29):4521-30
7. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110-20
8. Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, García-Laraña J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529-34
9. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289-94
10. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, et al. Long term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group and university of Arkansas for medical sciences. J Clin Oncol. 2010,28(7):1209-14
11. Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, et al. Influence of pre-and post transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775-82
12. Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognosis subgroup of symptomatic multiple myeloma patients. Blood. 2009;114(20): 4369-72
13. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, et al. Major tumor shrinking and persistent molecular remissions after consolidation with Bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077-84
14. Harousseau JL, Attal M, Avet-Loisseau H. The role of complete response in multiple myeloma. Blood. 2009;114(15):3139-46
15. Landgren O, Kyle RA, Pfeiffer RM. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-7
16. Rawstron AC, Benneth FJ, O ́Connor SJ. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. N Engl J Med. 2008;379(6): 575-83
17. Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115(21):4168-73
18. San Miguel JF, Almeida J, Mateo G, Bladé J, López-Berges C, Caballero D, et al. Inmunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002;99(5):1853-6
19. Sarasquete ME, García-Sanz R, González D, Martínez J, Mateo G, Martínez P, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide realtime quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365-72
20. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, et al. Magnetic resonance imaging in multiple myeloma diagnostic and clinical implications. J Clin Oncol. 2007;25(9):1121-8
21. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18 fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009:114(10):2068-76
22. Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, et al. 18F-FDG PET/CT 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med. 2008;49(2):195-200
23. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet. 2010;376(9758):2075-85
24. van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, et al. Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy. Blood. 2010;116(8):1220-7.